Pharmaceutical

Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

May 2, 2025 - 06:00
Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy
Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.
Read the original article

Tags:

Previous Article

Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off

Next Article

New £1bn cancer research hub planned for South London

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ‘A tug of war’: Europe braces for new legislation with far-reaching impacts on pharma and patients

STAT+: ‘A tug of war’: Europe braces for new legislatio...

Apr 25, 2023

Futura Medical and Haleon partner to commercialise Eroxon gel in US

Futura Medical and Haleon partner to commercialise Erox...

Jul 17, 2023

NICE recommends Lilly’s tirzepatide to treat T2D

NICE recommends Lilly’s tirzepatide to treat T2D

Sep 9, 2023